Big announcement and Hepatic impairment studies (Ep. 22)
From Clinical Pharmacology Podcast with Nathan Teuscher · · 18 min
This plays from the publisher's own server. We do not host a copy.
Description
Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.
Links discussed in the show:
- FDA guidance (https://go.teuschersolutions.com/hepaticfda)
- EMA guideline (https://go.teuschersolutions.com/hepaticema)
- Aplos Analytics website (https://aplosanalytics.com)
- You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message
- Send me a message (https://go.teuschersolutions.com/contact)
- Sign up for my newsletter (https://go.teuschersolutions.com/newsletter)
Copyright Teuscher Solutions LLC
Back to Clinical Pharmacology Podcast with Nathan Teuscher · Report a problem